Lanreotide/octreotide/sunitinibLack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1911卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17556-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：259 / 259

相关论文

共 50 条

[1] Everolimus/Lanreotide/SunitinibLack of efficacy
[J]. Reactions Weekly, 2024, 2013 (1) : 195 - 195
[2] SunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2022, 1907 (1) : 438 - 438
[3] SunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2022, 1888 (1) : 315 - 315
[4] SunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2023, 1959 (1) : 597 - 597
[5] SunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2022, 1925 (1) : 463 - 463
[6] SunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2022, 1928 (1) : 337 - 337
[7] Docetaxel/sunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2021, 1854 (1) : 137 - 137
[8] Lanreotide/octreotide withdrawalCholelithiasis (first report with lanreotide): 5 case reports
[J]. Reactions Weekly, 2007, 1157 (1) : 16 - 16
[9] Lanreotide/octreotide/pasireotideLack of efficacy
[J]. Reactions Weekly, 2024, 2016 (1) : 262 - 262
[10] Axitinib/bevacizumab/sunitinibLack of efficacy: case report
[J]. Reactions Weekly, 2023, 1964 (1) : 86 - 86

← 1 2 3 4 5 →